Targeting the microenvironment in solid tumors.

Tumorigenesis is a complex and dynamic process involving different cellular and non-cellular elements composed of tumor microenvironment (TME). The interaction of TME with cancer cells is responsible for tumor development, progression and drug resistance. TME consists of non malignant cells of the tumor such as cancer associated fibroblasts (CAFs), endothelial cells and pericytes composing tumor vasculature, immune and inflammatory cells, bone marrow derived cells, and the extracellular matrix (ECM) establishing a complex cross-talk with tumor. These interactions contribute towards proliferation and invasion of the tumor by producing growth factors, chemokines and matrix-degrading enzymes. ECM is a complex system containing macromolecules with distinctive physical, biochemical and biomechanical properties. During tumorigenesis this system is deregulated favoring the generation of tumorigenic microenvironment enhancing tumor-associated angiogenesis and inflammation. An important step of anticancer treatment is the identification of the biological alterations present in TME in order to target these key molecular players. Multitargeted approaches, providing a simultaneous inhibition of TME components, may offer a more efficient way to treat cancer. In this manuscript we overview the function of each components of TME and the treatments targeting the key players.

[1]  J. Berzofsky,et al.  Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma , 2014, PloS one.

[2]  M. van de Rijn,et al.  Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.

[3]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[4]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Desai,et al.  The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[6]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[7]  I. Macreadie,et al.  Direct integrin αvβ6-ERK binding: implications for tumour growth , 2002, Oncogene.

[8]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[9]  D. Heitjan,et al.  Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients , 2013, Oncoimmunology.

[10]  J. Wolchok,et al.  Targeting T Cell Co-receptors for Cancer Therapy. , 2016, Immunity.

[11]  E. Stanley,et al.  Colony-stimulating factor-1 in immunity and inflammation. , 2006, Current opinion in immunology.

[12]  R. Hoffman,et al.  A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. , 2013, Blood.

[13]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[14]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[15]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[16]  R. Ramlau,et al.  Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Y. Maru,et al.  Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis , 2011, Oncogene.

[18]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[19]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[20]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[21]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[22]  S. Ugel,et al.  Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. , 2015, The Journal of clinical investigation.

[23]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[24]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[25]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[26]  Hong Zhang,et al.  Cellular response to hypoxia involves signaling via Smad proteins. , 2003, Blood.

[27]  C. Piccirillo,et al.  Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.

[28]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[30]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[31]  P. V. van Diest,et al.  Hypoxia‐inducible factor‐1α is associated with angiogenesis, and expression of bFGF, PDGF‐BB, and EGFR in invasive breast cancer , 2005 .

[32]  Z. Werb,et al.  Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.

[33]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[34]  J. Riezu-Boj,et al.  Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. , 2011, Cancer research.

[35]  E. Voest,et al.  Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. , 2010, Neoplasia.

[36]  E. Hay,et al.  Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. , 2005, Cells, tissues, organs.

[37]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[38]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[40]  Richard O Hynes,et al.  The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. , 2012, Cancer discovery.

[41]  J. Hamilton,et al.  Control of macrophage lineage populations by CSF‐1 receptor and GM‐CSF in homeostasis and inflammation , 2012, Immunology and cell biology.

[42]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[43]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[44]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[45]  Alison Martin,et al.  Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. , 2015, Future oncology.

[46]  R. Greil,et al.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[47]  Y Quijano,et al.  Stromal disrupting effects of nab-paclitaxel in pancreatic cancer , 2013, British Journal of Cancer.

[48]  A. Harris,et al.  A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[49]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[50]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[51]  T. Bekaii-Saab,et al.  Disrupting Cytokine Signaling in Pancreatic Cancer: A Phase I/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease , 2013, Pancreas.

[52]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[53]  F. Finkernagel,et al.  The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization , 2016, Oncotarget.

[54]  I. Pinchuk,et al.  PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. , 2008, Gastroenterology.

[55]  S. H. van der Burg,et al.  A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  E. Perez,et al.  RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  H. Kaufman,et al.  OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. , 2010, Future oncology.

[58]  I. Kerr,et al.  Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon , 1990, Cell.

[59]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[60]  A. Heitger Regulation of expression and function of IDO in human dendritic cells. , 2011, Current medicinal chemistry.

[61]  P. Carmeliet Angiogenesis in health and disease , 2003, Nature Medicine.

[62]  G. Hu,et al.  New horizons in tumor microenvironment biology: challenges and opportunities , 2015, BMC Medicine.

[63]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[64]  Nels C. Elde,et al.  Protein kinase R reveals an evolutionary model for defeating viral mimicry , 2008, Nature.

[65]  E. Small,et al.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Ana C Anderson,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[67]  Yuquan Wei,et al.  Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.

[68]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[69]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  G. Coukos,et al.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales , 2011, Nature Reviews Immunology.

[71]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[72]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Li Yang,et al.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. , 2010, Trends in immunology.

[74]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[75]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[76]  J. Wolchok,et al.  Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.

[77]  J. Soria,et al.  Annals of Oncology , 2022 .

[78]  C. Carman,et al.  Structural basis of integrin regulation and signaling. , 2007, Annual review of immunology.

[79]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[80]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[81]  M. Ashcroft,et al.  Hypoxia‐inducible factor‐1 and oncogenic signalling , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[82]  S. Steinberg,et al.  Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors , 2011, Clinical Cancer Research.

[83]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[84]  E. Van Cutsem,et al.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.

[85]  M. Karin,et al.  Signal transduction by tumor necrosis factor and its relatives. , 2001, Trends in cell biology.

[86]  B. Aggarwal,et al.  Role of nuclear factor-κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents , 2011, Experimental biology and medicine.

[87]  G. Ahn,et al.  Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature , 2009, Angiogenesis.

[88]  S. Rafii,et al.  The bone marrow vascular niche: home of HSC differentiation and mobilization. , 2005, Physiology.

[89]  A. Tolcher,et al.  Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.

[90]  Beverly A. Teicher,et al.  Transforming Growth Factor-β and the Immune Response to Malignant Disease , 2007, Clinical Cancer Research.

[91]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[92]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[93]  Dana M. Brantley-Sieders,et al.  Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. , 2009, Cancer research.

[94]  Hae-Yun Jung,et al.  Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis , 2014, Clinical Cancer Research.

[95]  J. Larkin,et al.  A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma , 2010, British Journal of Cancer.

[96]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[97]  Andreas Sashegyi,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.

[98]  J. Blay,et al.  CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. , 2015, The Lancet. Oncology.

[99]  M. Gore,et al.  Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[101]  F. Richards Molecular pathology of von Hippel–Lindau disease and the VHL tumour suppressor gene , 2001, Expert Reviews in Molecular Medicine.

[102]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[103]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[104]  Z. Werb,et al.  Extracellular matrix degradation and remodeling in development and disease. , 2011, Cold Spring Harbor perspectives in biology.

[105]  D. Lyden,et al.  The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.

[106]  A B West,et al.  Myofibroblasts: paracrine cells important in health and disease. , 2000, Transactions of the American Clinical and Climatological Association.

[107]  G. Scagliotti,et al.  Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[109]  A. Ribas,et al.  Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.

[110]  C. Nelson,et al.  New insights into the regulation of epithelial-mesenchymal transition and tissue fibrosis. , 2012, International review of cell and molecular biology.

[111]  B. Hinz,et al.  Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.

[112]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[113]  Dong Eun Kim,et al.  Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation , 2015, Nature Cell Biology.

[114]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[115]  R. Salazar,et al.  Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.